ECSP10010152A - Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa - Google Patents

Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa

Info

Publication number
ECSP10010152A
ECSP10010152A EC2010010152A ECSP10010152A ECSP10010152A EC SP10010152 A ECSP10010152 A EC SP10010152A EC 2010010152 A EC2010010152 A EC 2010010152A EC SP10010152 A ECSP10010152 A EC SP10010152A EC SP10010152 A ECSP10010152 A EC SP10010152A
Authority
EC
Ecuador
Prior art keywords
pharmaceutically acceptable
combination
oract
strategen
gestagen
Prior art date
Application number
EC2010010152A
Other languages
English (en)
Inventor
Beate Burglen
Manuela Pfeifer
Sabine Fricke
Claus Claussen
Ralf Ladwig
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ECSP10010152A publication Critical patent/ECSP10010152A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

. Los gestágenos, con preferencia dienogest, acetato de clormadinona o levornogetrel en combinación con estrógenos tales como, por ejemplo, etinilestradiol, 17ß-estradiol o valerato de estradiol y uno o varios excipientes/portadores farmacéuticamente aceptables realizan una anticoncepción oral sin lactosa. Se da una posibilidad para mejorar la prevención de la intolerancia a la glucosa en un factor que eventualmente contribuye con la mejoría, incluso en cuanto a costosos ensayos de la intolerancia a la glucosa. La invención también es apropiada para un uso prolongado.
EC2010010152A 2007-11-05 2010-05-05 Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa ECSP10010152A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07021465A EP2055306A1 (de) 2007-11-05 2007-11-05 Verwendung eines Gestagens in Kombination mit einem Estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/Trägern zur laktosefreien oralen Kontrazeption

Publications (1)

Publication Number Publication Date
ECSP10010152A true ECSP10010152A (es) 2010-06-29

Family

ID=39016019

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010152A ECSP10010152A (es) 2007-11-05 2010-05-05 Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa

Country Status (30)

Country Link
EP (3) EP2055306A1 (es)
JP (1) JP2011502136A (es)
KR (1) KR20100103794A (es)
CN (1) CN101848716B (es)
AR (1) AR069195A1 (es)
AT (1) AT12800U1 (es)
AU (1) AU2008324549A1 (es)
BR (1) BRPI0819189A2 (es)
CA (1) CA2704523A1 (es)
CO (1) CO6270329A2 (es)
CR (1) CR11413A (es)
DE (1) DE202007019049U1 (es)
DK (1) DK2217243T3 (es)
DO (1) DOP2010000130A (es)
EA (1) EA201000749A1 (es)
EC (1) ECSP10010152A (es)
ES (1) ES2511841T3 (es)
HR (1) HRP20140962T1 (es)
IL (1) IL205349A0 (es)
MX (1) MX2010004975A (es)
NZ (1) NZ585065A (es)
PA (1) PA8803001A1 (es)
PE (1) PE20091020A1 (es)
PL (1) PL2217243T3 (es)
PT (1) PT2217243E (es)
SG (1) SG188118A1 (es)
TW (1) TW200936142A (es)
UY (1) UY31454A1 (es)
WO (1) WO2009059690A1 (es)
ZA (1) ZA201004024B (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368373A1 (en) * 1988-10-13 1990-05-16 Akzo Nobel N.V. Multi-phase contraceptive preparation
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JPH1171268A (ja) * 1997-08-28 1999-03-16 Kayaku:Kk 性ホルモン含有錠剤
CA2260673A1 (en) 1999-02-04 2000-08-04 Natrel Inc. A process for making a lactose-free milk without negatively affecting the organoleptic properties thereof; and milk so processed
DE10043846A1 (de) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
FR2832065B1 (fr) * 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
WO2005030176A1 (en) 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Improved stability of progestogen formulations
WO2005030175A1 (en) 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Hrt formulations
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
DE102004019406A1 (de) * 2004-04-19 2005-11-03 Schering Ag 17α-Fluorsteroide
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
EP1690543A1 (de) * 2005-02-15 2006-08-16 Schering AG Pharmazeutisches Präparat zur Kontrazeption
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest

Also Published As

Publication number Publication date
SG188118A1 (en) 2013-03-28
ZA201004024B (en) 2012-11-28
IL205349A0 (en) 2010-12-30
EP2774614A1 (de) 2014-09-10
DOP2010000130A (es) 2010-07-31
NZ585065A (en) 2012-06-29
PE20091020A1 (es) 2009-08-15
HK1145289A1 (en) 2011-04-15
KR20100103794A (ko) 2010-09-28
PT2217243E (pt) 2014-09-24
EP2217243A1 (de) 2010-08-18
EP2055306A1 (de) 2009-05-06
EP2217243B1 (de) 2014-08-06
PA8803001A1 (es) 2009-06-23
ES2511841T3 (es) 2014-10-23
UY31454A1 (es) 2009-05-29
JP2011502136A (ja) 2011-01-20
HRP20140962T1 (hr) 2014-12-05
DE202007019049U8 (de) 2010-09-30
CO6270329A2 (es) 2011-04-20
DE202007019049U1 (de) 2010-05-12
CR11413A (es) 2010-06-17
PL2217243T3 (pl) 2014-12-31
BRPI0819189A2 (pt) 2015-05-26
AT12800U1 (de) 2012-11-15
CN101848716A (zh) 2010-09-29
MX2010004975A (es) 2010-05-24
CN101848716B (zh) 2012-11-28
WO2009059690A1 (de) 2009-05-14
AU2008324549A1 (en) 2009-05-14
DK2217243T3 (da) 2014-10-20
AR069195A1 (es) 2010-01-06
TW200936142A (en) 2009-09-01
EA201000749A1 (ru) 2010-12-30
CA2704523A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
Schindler The “newer” progestogens and postmenopausal hormone therapy (HRT)
ATE493132T1 (de) Arzneimittel umfassend wenigstens ein gestagen
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
IN2012DN04867A (es)
PE20120860A1 (es) Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
CL2011003172A1 (es) Composicion farmaceutica que comprende a) un excepiente, b) al menos un precursor de esteroides sexuales, c) al menos un modulador selectivo del receptor de estrogenos o una antiestrogeno y no contiene una progestina y/o un estrogeno; kit farmaceutico; y uso para reducir o eliminar sofocos, sintomas vasomotores y sudores nocturnos.
EP4335501A3 (en) Use of estriol in low doses
CR10732A (es) Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
PE20070327A1 (es) Composicion que comprende una progestina y un estrogeno
BRPI0512993A (pt) uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto
DK1443966T3 (da) Fremgangsmåde til forebyggelse eller behandling af benigne gynækologiske lidelser
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
JP2008515909A5 (es)
NO20072893L (no) Fast, peroralt prevensjonsmiddel
ECSP10010152A (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
CL2008000999A1 (es) Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
CU20100084A7 (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
MX2009000950A (es) Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos.
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
CR11211A (es) Estratienos 8-beta-sustituidos como estrogenos de accion selectiva
GEP20135792B (en) Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and use of the same
AR053546A1 (es) Forma farmacologica peroral solida para la anticoncepcion